Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and other forms of leukemia.
Our primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of pa...
Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and other forms of leukemia.
Our primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and other forms of leukemia. Our primary indication